Articles On Dimerix (ASX:DXB)

“Your Stock Request” is a weekly video where we analyse share price charts for stocks on the Australian market (ASX) as requested by you! Email us at [email protected] with your stock request. Limit of one per person, no guarantee o...

Morgans says economic challenges have been catalyst for innovation and resilience in ASX health sector PharmAust submits supplementary data to US FDA from Phase 1 MEND study in support of its ODD request Singular health gets $1 million bac...

Morgans says more money could flow into ASX healthcare sector in 2024 as higher interest rate cycle stabilises Nyrada soars after lead drug candidate demonstrates strong efficacy in reducing secondary brain injury in animal study   Dimerix...

Dimerix (ASX:DXB) has announced it has received firm commitments to raise $20 million via an institutional placement with proceeds to complete the ACTION3 Phase 3 clinical study in patients with debilitating kidney disease.

  Local markets gives up early gains, ekes out 0.1pc advantage IT and Utilities offset by Energy sector losses Small Caps led by RMI and Narryer Metals   We’re slightly higher at match out in Sydney. But big banks became bad banks after l...

Dimerix secures firm commitments for a $20m institutional placement ‘Highly strategic’ capital raise will see new institutional investors join the company’s register Proceeds will be used to advance the ACTION3 Phase 3 trial of DMX-200 in...

Dimerix Ltd (ASX: DXB) shares are taking off on Tuesday. In morning trade, the ASX healthcare stock is up 20% to a 52-week high of 36 cents. Why is this ASX healthcare stock jumping? The catalyst for this rise has been the successful compl...

Our 2021 Biotech Pick of the Year Dimerix (ASX:DXB), just announced success on its interim Phase III clinical trial for FSGS - a rare kidney disease.

  Local markets get smashed, drop 1.8pc All 11 ASX sectors down Small Caps led by Task Group   A record close on Friday has found a typically ASX200-flavoured follow-up on Monday after the last session in New York saw US semiconductor dar...

  Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis using proteinuria efficacy endpoint DMX-200 performing better than placebo in reducing proteinuria in patients with FSGS The trial’s IDMC says it has no safety conc...

Dimerix ACTION3 Phase 3 trial successfully passes first interim analysis endpoint Mesoblast says US FDA supports accelerated approval pathway for rexlemestrocel-L Imexhs raises $1.5 million in cap raise to sophisticated and institutional i...

There’s expected to be a more lacklustre session on the ASX200, after last week’s record-breaking performances. Futures tips the market will be down around about a half a per cent. US markets lost their steam on Friday and that saw te...

ASX Health Index down -1.5% for February 76 biotechs rose, and 78 fell during the month But essentially, biotech is a long term game for investors   The S&P/ASX 200 Health Care [XHJ] struggled in February, finishing -1.5% lower and tr...

Local markets end slightly higher IT Sector slumps 1.2pc Small Caps led by AT1   The ASX 200 traded sideways again today, closing the day +0.1% higher as gains in Financials and Real Estate were offset by losses in Tech and Mining stocks....

Viking Therapeutics doubled after results of weight loss drug trial Janux Therapeutics tripled on pancreatic cancer results We look at the recent best performing ASX health stocks   There were a couple of big news from the world of biotec...

  Local markets end +0.13% higher in quasi-comeback Consumer Staples soar on bumper Coles news, but offset by everyone else Small Caps led by Audeara on the back of a massive manufacturing sale   The indignation of Coles has led Consumer...

Dimerix (ASX:DXB) has announced that data from the first 72 patients randomised in the ACTION3 Phase 3 trial of DMX-200 in patients with focal segmental glomerulosclerosis has successfully been collected.

Dimerix first analysis results of Phase III trial into focal segmental glomerulosclerosis (FSGS) due in March Results are key milestone for Dimerix which has been working on its lead asset DMX-200 since around 2012 Dimerix finalised its fi...

  ASX200 drops about 0.7pc on Wednesday Consumer Staples craters, as WOW CEO departs Small Caps led by diggers IXR, AW1 and the biopharma Alterity   The ASX200 has ended lower on Wednesday, tracking losses in New York as traders brace – a...

Dimerix receives approval of investigational new drug application for ACTION3 trial in China No bridging studies required in the Chinese population prior to recruitment for trial Dimerix says the milestone approval may support partnering d...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, that made announcements today.   ICYMI Leade...

Dimerix (ASX:DXB) secures approval from the Chinese NMPA Centre for Drug Evaluation (CDE) for its IND application The approval greenlights the recruitment of 70 clinical sites across 11 countries, with further expansion plans post the an...

Dimerix (ASX:DXB) has announced that Chinese National Medical Products Administration Center for Drug Evaluation has approved an Investigational New Drug application to commence recruitment for ACTION3 Phase 3 study of DMX-200 for f...

Xi and Biden set to agree on restricting fentanyl  Fentanyl is a synthetic opioid responsible for the opioids epidemic in the US We look at the best performing health stocks over the past couple of weeks   China’s President Xi is expected...

Australian company Dimerix (ASX:DXB) has received an initial payment of €6.5 million ($10.7 million) from its partner, UK-based Advanz Pharma.

Dimerix (ASX:DXB) receives an initial upfront payment of €6.5 million (A$10.7 million) from Advanz Pharma As part of the agreement, Advanz has been granted rights to market DMX-200 for FSGS within the European Economic Area, the UK, Swit...

Shares in All Ordinaries Index (ASX: XAO) stock Pacific Current Group Ltd (ASX: PAC) have jumped more than 8% today on takeover news related to GQG Partners Inc (ASX: GQG). Pacific Current owns stakes in fund managers from around the world...

The S&P ASX 200 fell -3.8% in October with mid-caps falling -6.94% and small-caps down -5.45% for the month S&P ASX 200 Energy was the only sector that closed October in the black with all Australian equity factors in red Dimerix...

Share prices are always changing on the stock market, so different opportunities are opening up. A fund manager has highlighted two All Ordinaries Index (ASX: XAO) shares that could be very appealing to investors. The fund manager in quest...

News relating to Novo Nordisk’s Ozempic has led to a selloff in some ASX stocks CSL, FPH, and RMD fell heavily last week But Goldman analysts say they won’t change ratings on these 3 stocks   Goldman Sachs analysts said they will make no...

Investors are always warned to be careful, or even suspicious, of high dividend yields. That's because lofty yields can easily be a trap, where a declining share price ends up cancelling out all the received distributions — or worse. So wh...

Ask any chief of a development-stage biotech about the prospect of a partnering or licencing deal and they will refer to a multitude of discussion with big pharma – all couched in suitably vague terms. But when Dimerix (ASX:DXB) chief Dr Ni...

ASX 200 closes higher for a fifth straight day All 11 Sectors make it home for supper Small caps led by Zuleika and Creasy   It’s fair to say the little battler of an Aussie sharemarket’s put in a real decent day’s work. As various part...

This week’s Bulls N’ Bears top ASX runner is… Noxopharm. It skyrocketed 323 per cent to join other impressive runners including Dimerix, Roots Sustainable Agricultural Technologies and Toys“R”Us.

Benchmark index finishes Friday ahead +0.4% Sectors led by Financials Small caps dominated by Dimerix   The ASX200 is up +0.4% at  the end of Friday trade, making the week a 1% loss, which we’ll take at this stage. US equities ticked l...

Investing in bonds is a topic that has been growing in interest in recent months. With inflation remaining stubbornly sticky in most advanced economies, compounded by rising oil prices, fears that interest rates may not have peaked just ye...

ASX health sector falls in line with broader markets as macroeconomic factors continue to create volatility Dimerix soars on $230m licensing deal with ADVANZ PHARMA for DMX-200 into rare kidney disease US FDA approves Cyclofarm’s lung imag...

The S&P/ASX 200 Index (ASX: XJO) is on course to end the week on a positive note. In afternoon trade, the benchmark index is up 0.7% to 6,972.3 points. Four ASX shares that are rising more than most today are listed below. Here's why...

The Dimerix Ltd (ASX: DXB) share price is rising strongly for a second day in a row. So much so, at one stage today, the ASX healthcare share was up a further 48% to a 52-week high of 23 cents. When Dimerix's shares reached that level, it...

The Australian sharemarket rebounded from 11-month lows on Thursday, notching a small gain as markets braced for the official US jobs data on Friday night Australian time. The benchmark S&P/ASX 200 (INDEXASX: XJO) index gained 35.3 poin...

Benchmark index finds some rare greenage, up 0.5% Property and IT Sectors lead broad-based gains, XEC Emerging Co’s index now down 14% from July highs Fascinating small caps action: led by Dimerix, Bluglass and Experience Co.   The ASX2...

The ASX200 has broken its drought, managing to pick up half a per cent by the end of trade today.   Most sectors are in the green, with real estate the leader climbing two per cent. Those that struggled were energy, down nearly a per...

Stockhead’s In-Case-You-Missed-It highlights today’s most interesting small cap stories that might have slipped beneath your radar. Below is a wrap of the top 20 performing stocks, by percentage, who made announcements today.   ICYMI Leader...

On Thursday, the sharemarket experienced a rebound, influenced by a relief rally inspired by Wall Street. This rally was prompted by softer US jobs data, which temporarily alleviated concerns about high interest rates. However, the gains in...

  Dimerix partners with ADVANZ Pharma to commercialise DMX-200 for treatment of rare kidney disease Dimerix to receive up to ~AU$230 million in upfront and milestone payments, plus royalties ADVANZ to leverage its specialty, hospital, and...

Drug development company Dimerix (ASX: DXB) has secured a licencing deal with Advanz Pharma Corp for the commercialisation of Dimerix’s Phase 3 drug candidate DMX-200 to treat focal segmental glomerulosclerosis (FSGS) kidney disease. The ag...

In August, Australia's trade surplus expanded to $9.6 billion, surpassing expectations, as exports increased by 4 percent, primarily led by gold, while imports declined by 0.4 percent, largely due to a decrease in industrial transport equip...

05 Oct 2023 - A snapshot of the stocks on the move, featuring Vintage Energy (ASX:VEN), Rumble Resources (ASX:RTR), QX Resources (ASX:QXR), Dimerix (ASX:DXB) and BluGlass (ASX:BLG)…

  Vintage Energy (ASX:VEN) announces an additional two-year gas sale under the master gas supply agreement for the Odin gas field. The joint venture parties have agreed and signed terms with Pelican Point Power for the supply of gas from 1...

The Dimerix Ltd (ASX: DXB) share price has returned from its trading halt with a bang on Thursday. In morning trade, the ASX healthcare share was up a massive 130% to 14 cents. It has since pulled back but remains up an impressive 89% to 1...